New Strain Of Medicinal Marijuana Announced
First Unveiling of New Strain To Redefine The Medical Cannabis Industry
New Released Scientific Data Supports Medicinal Value, U.S. Government Ignores Scientific Data
Next week’s Patients Out of Time (P.O.T.) conference in Rhode Island features numerous speakers and interesting topics, but the announcement by Harborside Health Center of the development a new Cannabidol-centric strain of cannabis I suspect will be of great interest to patients, medical providers and cultivators.
I think it also a shining example of why the Drug Enforcement Administration should not bust and harass laboratories contracted or operated by cannabis wellness centers that test and analyze cannabis that is sold into the medical collective for the very reason that these forensic labs provide necessary patient information regarding potency, purity and medicinal effects based on plant strain.
Oakland, CA – The availability of a new type of medical cannabis strain will be presented for the first time by Steve DeAngelo, who has been featured on CNN, The Wall Street Journal, Fortune Magazine, and The New York Times as Executive Director of one of the nation’s top model and non-profit medical cannabis dispensaries, Harborside Health Center in Oakland, California.
DeAngelo will announce the availability of this type of non-psychoactive cannabis that has been lab tested with California strains with CBD (Cannabidol) at the 6th Annual National Clinical Conference on Cannabis Therapeutics on Friday, April 16th at 12PM Noon at The Crown Plaza Hotel, 801 Greenwich Avenue, Warwick, Rhode Island.
Conference information can be found at: www.medicalcannabis.com
For three decades, DeAngelo has been an engaging speaker as he cuts through the stigma, and delivers the true facts about cannabis. His exciting and important presentation will include results of the first large scale analytical study of California’s medical cannabis supply, which revealed that one of the most medically efficacious cannabinoids—CBD—has been bred out of plants grown primarily for psychoactive effect. Only within the past year have CBD-rich cannabis varieties been identified, thanks to an analytical chemistry lab that DeAngelo helped launch.
Recent research has demonstrated that CBD is effective in slowing or reversing a number of different types of cancer; as well as other serious illnesses. In response to the shortage of CBD rich cannabis varieties, Harborside has initiated a program to identify such strains, and encourage growers to propagate them. Because CBD modulates the psycho activity of THC, some patients respond better to varieties of cannabis which couple low THC levels with high CBD levels, because they enhance medical efficacy while reducing or eliminating psycho activity. This is particularly true for cannabis-naïve patients, who have no prior experience with it, prior to receiving a recommendation from their doctor. “Ultimately, there will be greater demand for CBD-rich cannabis, than there is for cannabis that just gets you high” predicts DeAngelo. “Only a small percentage of people enjoy the psycho activity of cannabis, but almost everybody can benefit from its medical properties”.
The 6th Annual Clinical Conference on Cannabis Therapeutics is the only one of its kind in the United States for health professional to learn about the many benefits of cannabis therapeutics. Medical professionals can receive their CME (Continuing Education) credits for attending this forum through the University of California, San Francisco.
The New York Times: “Harborside Health Center, a nonprofit medical marijuana dispensary in Oakland, Calif., is looked upon as a model of how others could operate.”
Contact : Gaynell Rogers/Media Relations
April 9, 2010